Cell-type Specific Neuromodulation Using Burst DBS Produces Long-lasting Behavioral and Physiological Rescue in a Parkinsonian Mouse Model
Project Number5F31NS127483-03
Contact PI/Project LeaderNANIVADEKAR, SHRUTI
Awardee OrganizationCARNEGIE-MELLON UNIVERSITY
Description
Abstract Text
PROJECT SUMMARY
Parkinson’s disease (PD) is a debilitating neurological disorder affecting up to 10 million people worldwide with
symptoms of tremor, bradykinesia, and rigidity that severely limit the quality of life of patients. Deep brain
stimulation (DBS) is an effective treatment used in patients who demonstrate symptoms that are inadequately
controlled by medications. This treatment involves the delivery of continuous high frequency stimulation to either
the subthalamic nucleus (STN) or the globus pallidus interna (GPi), two modulatory nuclei in the basal ganglia
(BG). DBS improves motor symptoms acutely but does not differentiate between neuronal circuits, and its effects
decay rapidly when stimulation is turned off. The need for constant stimulation increases the risk of side effects
and the frequency of battery replacement. Hence the investigation of alternative patterns of stimulation that
produce long-lasting recovery is critical. Such stimulation paradigms could minimize adverse outcomes caused
by constant current delivery while also inducing therapeutic plasticity in the form of reversal of the aberrant
synchronous activity of the BG seen in PD patients. Since the cellular mechanism of action of DBS is unknown,
the clinical advances in identifying these patterns have been limited. Recent findings in the Gittis lab suggest
that optogenetically manipulating distinct neuronal subpopulations (specifically, activating PV neurons and
inhibiting Lhx6 neurons) in the external globus pallidus (GPe), a central nucleus of the BG, provides long-lasting
reduction in immobility in dopamine-depleted mice that show bradykinesia or akinesia at baseline. In an effort to
make this finding translatable, using insights from the synaptic features of these cell-types, we identified that
electrical stimulation delivered in the entopeduncular nucleus (EPN, rodent homolog of the GPi) as bursts can
produce the same cell-type modulation described above. Such a DBS protocol when tested in vivo produced
motor recovery that lasted for hours after stimulation was stopped. These findings could hugely impact the
standard of care for Parkinson’s disease patients that show a narrow therapeutic window, by maximizing their
therapeutic duration, minimizing side effects, and potentially altering their pathological circuitry. The goal of this
proposal is to demonstrate a clinically translatable optimized burst DBS protocol which can produce long-lasting
motor recovery by reversing the underlying pathological activity in the BG. In an effort to optimize burst DBS
from a translational standpoint, Aim 1 will establish the combination of stimulation frequency and duration
required to see prolonged therapeutic benefits. To potentially accelerate the translation to PD patients with DBS
implants in the STN, the effect of burst DBS in the STN will be compared to burst DBS in the EPN. Since patients
show motor vs. non-motor symptoms at varying stages of the disease, Aim 2 will characterize the behavioral
effects of burst DBS on symptoms at varying levels of dopamine depletion. Finally, in an effort to understand the
underlying mechanism of the long-lasting motor rescue, Aim 3 will evaluate whether burst DBS induces
therapeutic plasticity by attenuating the pathological firing of Substantia nigra pars reticulata (SNr) neurons.
Public Health Relevance Statement
PROJECT NARRATIVE
Deep brain stimulation (DBS) effectively ameliorates motor symptoms in Parkinson’s disease (PD), however its
mechanism of action remains unclear, limiting further optimization of therapeutic efficacy. This study aims to
test how delivering burst DBS instead of continuous electrical stimulation can produce long-lasting motor
recovery by probing the behavioral effects, and the electrophysiological effects on the pathological synchrony
in the basal ganglia nuclei, at various disease stages. This investigation might add to our understanding of the
motor dysfunction in PD, while also providing further insights to new interventions in treating patients with PD.
NIH Spending Category
No NIH Spending Category available.
Project Terms
AccelerationAffectAnimalsAttenuatedBasal GangliaBehaviorBehavioralBiological MarkersBradykinesiaCell NucleusClinicalCoupledDataDeep Brain StimulationDiseaseDopamineDopamine ReceptorDoseElectric StimulationElectrophysiology (science)FiberFoundationsFrequenciesGangliaGlobus PallidusGoalsHistologyHomeoboxHomologous GeneHourHumanImmobilizationImplantIn VitroInterventionInvestigationKnowledgeMachine LearningMethodsModelingMotorMovementMovement DisordersMusNervous System DisorderNeuronsNeurosciencesParkinson DiseaseParvalbuminsPathologicPatientsPatternPersonsPharmaceutical PreparationsPhysiologicalProgressive DiseaseProtocols documentationQuality of lifeRecoveryResearchRiskRodentRoleStimulusStructure of subthalamic nucleusSubstantia nigra structureSymptomsSynapsesTestingTherapeuticTimeTranslationsTreatment EfficacyTremorWorkacute symptomadverse outcomebattery replacementcell typeclinical translationeffective therapyendopeduncular nucleusexperienceimprovedin vitro Modelin vivoin vivo evaluationinsightmotor disordermotor recoverymotor symptommouse modelneuralneuromechanismneuronal circuitryneuroregulationneurotransmissionnon-motor symptomoptimal treatmentsoptogeneticsparkinsonian rodentpower consumptionpreclinical studyside effectsignal processingskillsstandard of caresymptom treatment
National Institute of Neurological Disorders and Stroke
CFDA Code
853
DUNS Number
052184116
UEI
U3NKNFLNQ613
G4P3TF8PFH73
KZV2XNZZN3A8
MJ5BDF8KMQ43
U9C6D6YR7P69
Project Start Date
01-September-2022
Project End Date
31-August-2025
Budget Start Date
01-September-2024
Budget End Date
31-August-2025
Project Funding Information for 2024
Total Funding
$45,374
Direct Costs
$45,374
Indirect Costs
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Neurological Disorders and Stroke
$45,374
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5F31NS127483-03
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5F31NS127483-03
Patents
No Patents information available for 5F31NS127483-03
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5F31NS127483-03
Clinical Studies
No Clinical Studies information available for 5F31NS127483-03
News and More
Related News Releases
No news release information available for 5F31NS127483-03
History
No Historical information available for 5F31NS127483-03
Similar Projects
No Similar Projects information available for 5F31NS127483-03